This class action has been closed
Please note that at the end of this main information page there are links to view updated News and Court Documents as well as a Registration page to obtain a form to join the class action.
Wagners is one of seventeen law firms from across Canada who have agreed to co-operate and work in tandem to prosecute class actions against the makers of Vioxx on behalf of residents of Canada.
Vioxx is a Cyclooxgenase-2 (“Cox-2”) specific inhibitor in the class of drugs known as non-steroidal anti-inflammatory drugs (“NSAID”). By Notice of Compliance dated October 25, 1999, Vioxx was first approved for use in Canada as a Schedule “F” drug under the Canadian Food and Drugs Act. It was approved for acute and chronic treatment of the signs and symptoms of osteoarthritis, as well as for the relief of pain in adults and for the treatment of primary dysmenorrhea (menstrual pain).
On September 30, 2004, Merck announced a worldwide voluntary withdrawal of Vioxx, effective immediately, due to its increased risk of cardiovascular events, including heart attacks and strokes. It is alleged that Merck is collectively responsible for the manufacture, marketing, distribution, and sale of Vioxx in Canada.
Wagners issued a proposed class action on November 26, 2004 on behalf of its client, Hugh F. Card, and on behalf of other Nova Scotia residents who have suffered Vioxx-related injuries.
Update – July 29, 2008
The National Group of law firms were successful in obtaining certification of the class action.